[en] The amino acid sequence of salmon calcitonin (SCT) differs considerably from that of the human hormone and specific antibodies (Ab) develop in a significant proportion of patients after parenteral or nasal administration of SCT. Controversy remains regarding the functional importance of these Ab. We report on the development of specific anti-SCT Ab in a population of postmenopausal women receiving nasal SCT for prevention of postmenopausal bone loss, and compare the effects of nasal SCT in women with or without Ab. Thirty-nine per cent of women developed Ab after 6 months of treatment with SCT, 52% after 12 months, and 61% after 18 and 24 months. After 24 months the AB titre was 3.47-17.7 x 10(-9) M/l (mean +/- SD: 13.3 +/- 3.1 x 10(-9) M/l). No significant differences appeared between the changes in lumbar bone mineral density (BMD) measured in the whole population (n = 44) (mean +/- SD: +1.06 +/- 3.9%), the patients without Ab (n = 17) (+0.05 +/- 3.7%) or in those with Ab (n = 27) (+1.7 +/- 4.6%). During the same period, a control population randomly assigned to a 500 mg/day calcium intake showed a significant loss of lumbar BMD (-4.57 +/- 4.9%) (p < 0.01). In conclusion, in healthy postmenopausal women nasal SCT seems to maintain the same preventive effect against bone loss whether or not Ab are present.
Disciplines :
Rheumatology
Author, co-author :
Reginster, Jean-Yves ; Université de Liège - ULiège > Département des sciences de la santé publique > Epidémiologie et santé publique
Gaspar, S
Deroisy, Rita ; Centre Hospitalier Universitaire de Liège - CHU > Médecine de l'appareil locomoteur
Zegels, Brigitte ; Université de Liège - ULiège > Département des sciences de la santé publique > Epidémiologie et santé publique
Franchimont, P.
Language :
English
Title :
Prevention of Osteoporosis with Nasal Salmon Calcitonin: Effect of Anti-Salmon Calcitonin Antibody Formation
Copp D.H., Davidson A.G.P. (1961) Direct humoral control of parathyroid function in the dog. Proc Soc Exp Biol Med 107:342-4.
Copp D.H., Cameron E.C., Cheney B.A., Davidson A.G.F., Henze K.G. (1962) Evidence for calcitonin: a new hormone from the parathyroid that lowers blood calcium. Endocrinology 70:638-49.
Bijvoet O.L.M., van der Sluys Veer J., Jansen A.P. (1968) Effects of calcitonin on patients with Paget's disease, thyrotoxicosis and hypercalcaemia. Lancet 1:876-81.
Haddad J.G., Birge S.J., Avioli L.V. (1970) Effects of prolonged thyrocalcitonin administration of Paget's disease of bone. N Engl J Med 283:549-55.
Woodhouse N.J.Y. (1974) Clinical applications of calcitonin. Br J Hosp Med 1:677-84.
Singer F.R., Aldred J.P., Neer R.M., Krane S.M., Potts J.T., Bloch K.J. (1972) An evaluation of antibodies and clinical resistance to salmon calcitonin. J Clin Invest 52:2331-8.
Levy F., Muff R., Dotti-Sigrist S., Dambacher M.A., Fischer J.A. (1988) Formation of neutralizing antibodies during intranasal synthetic salmon calcitonin treatment of Paget's disease. The Journal of Clinical Endocrinology & Metabolism 67:541-5.
Reginster J.Y., Deroisy R., Denis D., Lecart M.P., Sarlet N., Franchimont P. (1988) Is there any place for salmon calcitonin in prevention of postmenopausal bone loss?. Gynecol Endocrinol 2:195-204.
Grauer A., Raue F., Schneider H.G., Frank-Raue K., Ziegler R. (1990) In vitro detection of neutralizing antibodies after treatment of Paget's disease of bone with nasal salmon calcitonin. J Bone Miner Res 5:387-91.
Muff R., Dambacher M.A., Fischer A. (1991) Formation of neutralizing antibodies during intranasal synthetic salmon calcitonin treatment of postmenopausal osteoporosis. Osteoporosis Int 1:72-5.
Singer F.R., Fredericks R.S., Minkin C. (1980) Salmon calcitonin therapy for Paget's disease of bone: the problem of acquired resistance. Arthritis Rheum 23:1148-53.
Rojannasathit S., Rosenberg E., Haddad (1974) Paget's bone disease: response to human calcitonin in patients resistant to salmon calcitonin. Lancet 2:1412-25.
Singer F.R., Villanueva R., Ginger K. (1989) Acquired resistance to salmon and human calcitonin during treatment of Paget's disease of bone. Calcif Tissue Int 87:32.
Martin T.J. (1979) Treatment of Paget's disease with calcitonins. Aust NZ J Med 9:36-43.
Woodhouse N.J.Y., Mohamedally S.M., Saed-Nejad F., Martin T.J. (1977) Development and significance of antibodies to salmon calcitonin in patients with Paget's disease on long-term treatment. BMJ 2:927-9.
Reginster J.Y., Gennari C., Mautalen C. (1990) Influence of specific anti-salmon calcitonin antibodies on biological effectiveness of nasal salmon calcitonin in Paget's disease of bone. Scand J Rheum 19:83-6.
Gennari C., Chierichetti S.M., Bigazzi S. (1985) Comparative effects on bone mineral content of calcium and calcium plus salmon calcitonin given in two different regimens in postmenopausal osteoporosis. Curr Therap Res 38:455-64.
Mazzuoli G.F., Passeri M., Gennari C. (1986) Effects of salmon calcitonin in postmenopausal osteoporosis: a controlled double-blind study. Calcif Tissue Int 38:3-8.
Overgaard K., Riis B.J., Christiansen C., Hansen M.A. (1989) Effect of salcatonin given intranasally on early postmenopausal bone loss. BMJ 299:477-9.
Overgaard K., Riis B.J., Christiansen C., Podenphant J., Johansen J. (1989) Nasal calcitonin for treatment of established osteoporosis. Clin Endocrinol 30:435-42.
Reginster J.Y., Denis D., Albert A. (1987) One-year controlled randomization trial of prevention of early postmenopausal bone loss by intranasal calcitonin. Lancet 2:1481-3.
Krolner B., Porsnielsen S. (1969) Measurement of bone mineral content (BMC) of the lumbar spine: theory and application of a new time-dimensional dual photon attenuation method. Scand J Clin Lab Invest 40:653-63.
Reginster J.Y., Geusens P., Nijs J., Denis D., Franchimont P., Dequeker J. (1989) In vivo long-term precision of spinal bone mass measurement by dual photon absorptiometry. Bone Miner 6:225-9.
Greenwood F.C., Hunter W.M., Glover J.S. (1963) Preparation of iodine-131 labelled human growth hormone of high specific radioactivity. Biochem J 89:114-23.
Reginster J.Y., Aimer S., Gaspar S. (1989) Evidence that specific antibodies do not reduce salmon calcitonin activity in vivo. Antibody, Immunoconjugates and Radiopharmaceuticals 2:117-24.
Zerbe G.O. (1979) Randomization analysis of the completely randomized design extended to growth and response curves. J Am Statist Assoc 4:213-5.
Derose J., Singer F.R., Avramides A. (1974) Response of Paget's disease to porcine and salmon calcitonin. Am J Med 56:1090-8.
Reginster J.Y., Azria M., Gaspar S. (1992) Endogenous production of specific antibodies does not decrease hypocalcaemic response to calcitonin in young rabbits. Calcif Tissue Int 51:340-3.
Berson S.A., Yallow R.S., Bauman A., Rotschild M.A., Newerly K. (1956) Insulin I-131 metabolism in human subjects: demonstration of insulin binding globulin in the circulation of insulin treated subjects. J Clin Invest 35:170-90.
Roth J., Glick M., Klein L.A., Peterson M.J. (1966) Specific antibodies to vasopressin in man. J Clin Invest 26:671-5.
Elick R.A., Gill J.R., Berson S.A. (1967) Antibody and clinical resistance to parathormone. N Engl J Med 276:144-7.
Berson S.A., Yallow R.S. (1959) Quantitative aspects of the reaction between insulin-binding antibody. J Clin Invest 38:1996-2016.
Greenberg P.B., Doyle F.M., Fisher H.T. (1974) Treatment of Paget's disease of bone with synthetic human calcitonin. Am J Med 56:867-70.
Bouizar Z., Rostene W.H., Milhaud G. (1987) Down regulation of rat kidney calcitonin receptors by salmon calcitonin infusion evidenced by autoradiography. Proc Natl Acad Sci USA 84:5125-8.